Tissue microarrays (TMAs) for high‐throughput molecular pathology research

A rapidly increasing number of genes are being suspected to play a role in cancer biology. To evaluate the clinical significance of newly detected potential cancer genes, it is usually required to examine a high number of well‐characterized primary tumors. Using traditional methods of molecular pathology, this is a time consuming endeavor rapidly exhausting precious tissue resources. To allow for a high throughput tissue analysis we have developed a “tissue chip” approach (Kononen et al., Nat. Med. 1998;4:844–7). Using this tissue microarray (TMA) technology, samples from up to 1,000 different tumors are arrayed in one recipient paraffin block, sections of which can be used for all kind of in situ analyses. Section from TMA blocks can then be utilized for the simultaneous analysis of up to 1,000 different tumors on the DNA, RNA or protein level. TMAs allow a high throughput molecular analysis of thousands of tumors within a few hours. All currently available data have suggested that minute arrayed tissue specimens are highly representative of their donor tissues. There are multiple different types of TMAs that can be utilized in cancer research including multi tumor arrays (containing different tumor types), tumor progression arrays (tumors of different stages) and prognostic arrays (tumors with clinical endpoints). The combination of multiple different TMAs allows a very quick but comprehensive characterization of biomarkers of interest. We anticipate that the use of TMAs will greatly accelerate the transition of basic research findings to clinical applications. © 2001 Wiley‐Liss, Inc.

[1]  L. Penland,et al.  Use of a cDNA microarray to analyse gene expression patterns in human cancer , 1996, Nature Genetics.

[2]  M. Bittner,et al.  Expression profiling using cDNA microarrays , 1999, Nature Genetics.

[3]  M. Rubin,et al.  Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression. , 2000, Human pathology.

[4]  T C Gasser,et al.  Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. , 1999, Cancer research.

[5]  M. Rubin,et al.  Tissue microarray assessment of prostate cancer tumor proliferation in African- American and white men. , 2000, Journal of the National Cancer Institute.

[6]  Y. Chen,et al.  Detecting activation of ribosomal protein S6 kinase by complementary DNA and tissue microarray analysis. , 2000, Journal of the National Cancer Institute.

[7]  H. Moch,et al.  High-throughput tissue microarray analysis to evaluate genes uncovered by cDNA microarray screening in renal cell carcinoma. , 1999, The American journal of pathology.

[8]  J. Kononen,et al.  Multiple genes at 17q23 undergo amplification and overexpression in breast cancer. , 2000, Cancer research.

[9]  E Mahlamäki,et al.  Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays. , 1999, Journal of the National Cancer Institute.

[10]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[11]  H. Battifora The multitumor (sausage) tissue block: novel method for immunohistochemical antibody testing. , 1986, Laboratory investigation; a journal of technical methods and pathology.

[12]  H. Moch,et al.  Tissue microarrays for gene amplification surveys in many different tumor types. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[13]  L. Ayers APPLICATION OF THE TISSUE MICROARRAY (TMA) METHOD BY THE MIDREGION AIDS AND CANCER SPECIMEN BANK (ACSB) TO PREPARE STUDY SETS FROM HIV INFECTED AND CONTROL TISSUES: ABSTRACT 16 , 2000 .

[14]  T Hardmeier,et al.  High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. , 2000, The American journal of pathology.